Date: 2016-03-16
Type of information: Opening of new premises
Compound:
Company: Vedanta Biosciences (USA - MA)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Infectious diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On March 16, 2016, Vedanta Biosciences announced that the company recently expanded into new headquarters and research and development facility in Cambridge, MA, including a state-of-the-art Good Manufacturing Practice (GMP) facility for the production of live bacterial drugs.
Vedanta Biosciences was founded by PureTech Health and a group of world-renowned experts in immunology and microbiology to pioneer the development of a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system. In January 2015, Vedanta announced a licensing agreement with Janssen Biotech.
Financial terms:
Latest news:
